Marshall Wace, LLP Repligen Corp Transaction History

Marshall Wace, LLP

$78.4 Billion
Q4 2024

A detailed history of Marshall Wace, LLP transactions in Repligen Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 412,235 shares of RGEN stock, worth $65.7 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

412,235

Previous 237,222 73.78%

Holding current value

$65.7 Million

Previous $35.3 Million 68.08%

% of portfolio

0.08%

Previous 0.05%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$123.41 - $160.92 $21.6 Million - $28.2 Million	175,013 Added 73.78%	412,235 $59.3 Million
Q3 2024 Nov 14, 2024	SELL	$119.79 - $167.35 $15.3 Million - $21.3 Million	-127,329 Reduced 34.93%	237,222 $35.3 Million
Q2 2024 Aug 14, 2024	BUY	$120.0 - $182.95 $463,680 - $706,918	3,864 Added 1.07%	364,551 $46 Million
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $6.82 Million - $8.32 Million	39,910 Added 12.44%	360,687 $66.3 Million
Q4 2023 Feb 14, 2024	SELL	$114.17 - $185.35 $1.54 Million - $2.5 Million	-13,502 Reduced 4.04%	320,777 $57.7 Million
Q3 2023 Nov 14, 2023	SELL	$138.78 - $176.51 $16 Million - $20.3 Million	-115,209 Reduced 25.63%	334,279 $53.2 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $36.4 Million - $47.5 Million	263,259 Added 141.36%	449,488 $63.6 Million
Q1 2023 May 15, 2023	BUY	$154.26 - $198.1 $19 Million - $24.4 Million	123,078 Added 194.89%	186,229 $31.4 Million
Q4 2022 Feb 14, 2023	SELL	$162.42 - $220.56 $21.3 Million - $28.9 Million	-131,164 Reduced 67.5%	63,151 $10.7 Million
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $28.6 Million - $45.7 Million	-178,562 Reduced 47.89%	194,315 $36.4 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $1.21 Million - $1.62 Million	8,630 Added 2.37%	372,877 $60.6 Million
Q1 2022 May 16, 2022	SELL	$161.19 - $257.96 $1.67 Million - $2.68 Million	-10,386 Reduced 2.77%	364,247 $68.5 Million
Q4 2021 Feb 14, 2022	SELL	$247.59 - $304.47 $36 Million - $44.3 Million	-145,497 Reduced 27.97%	374,633 $99.2 Million
Q3 2021 Nov 15, 2021	SELL	$194.77 - $324.21 $35.6 Million - $59.3 Million	-182,784 Reduced 26.0%	520,130 $150 Million
Q2 2021 Aug 13, 2021	SELL	$165.87 - $220.95 $39.9 Million - $53.2 Million	-240,810 Reduced 25.52%	702,914 $140 Million
Q1 2021 May 17, 2021	SELL	$180.37 - $226.26 $97 Million - $122 Million	-537,556 Reduced 36.29%	943,724 $183 Million
Q4 2020 Feb 16, 2021	BUY	$148.08 - $206.57 $84.9 Million - $118 Million	573,604 Added 63.19%	1,481,280 $284 Million
Q3 2020 Nov 16, 2020	BUY	$122.51 - $158.27 $32.4 Million - $41.9 Million	264,563 Added 41.14%	907,676 $134 Million
Q2 2020 Aug 13, 2020	BUY	$94.33 - $140.48 $7.41 Million - $11 Million	78,601 Added 13.92%	643,113 $79.5 Million
Q1 2020 May 15, 2020	BUY	$84.96 - $109.14 $48 Million - $61.6 Million	564,512 New	564,512 $54.5 Million
Q4 2019 Feb 14, 2020	SELL	$73.84 - $93.08 $471,468 - $594,315	-6,385 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$76.65 - $95.51 $7.93 Million - $9.89 Million	-103,501 Reduced 94.19%	6,385 $490,000
Q2 2019 Aug 14, 2019	BUY	$54.2 - $85.95 $5.96 Million - $9.44 Million	109,886 New	109,886 $9.45 Million
Q1 2019 May 14, 2019	SELL	$49.45 - $62.8 $205,959 - $261,562	-4,165 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$48.26 - $68.88 $201,002 - $286,885	4,165 New	4,165 $219,000

Others Institutions Holding RGEN

# of Institutions

482

Shares Held

56.3M

Call Options Held

251K

Put Options Held

458K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.84B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Repligen Corp Transaction History